Healthcare
RWS launches new linguistic validation service to significantly reduce clinical trial timelines
RWS (AIM: RWS.L), a global AI solutions company, today launched a new tech-enabled eCOA translation and linguistic validation service designed to help pharmaceutical companies, clinical research organizations (CROs) and eCOA providers reduce delays in global clinical trials.
About this update from Rws Holdings Plc
New service brings critical eCOA trial services together under one program team to speed global studies MAIDENHEAD, England, July 14, 2026 /PRNewswire/ -- RWS (AIM: RWS.L), a global AI solutions company, today launched a new tech-enabled eCOA translation and linguistic validation service designed to help pharmaceutical companies, clinical research organizations (CROs) and eCOA providers reduce delays in global clinical trials. The service brings together COA licensing, source validation, multilingual translation, Trados-enabled eCOA migration, intelligent workflows, rater training and dedicated program management under a single, integrated operating model – delivered by one program team with end-to-end governance and a single point of accountability across the entire COA lifecycle. Global clinical trials depend on precise timing, and language is often one of the greatest pressure points. In a global study, every week counts: sponsors need to move from instrument access to eCOA go-live without putting study start-up, site activation or regulatory submissions at risk. Yet many organizations still manage licensing, translation, eCOA migration and rater training across multiple vendors, systems and disconnected workstreams. The result is familiar – handoffs multiply, accountability blurs, visibility narrows, and small delays compound into significant operational and regulatory risk. RWS's service addresses this by redesigning the delivery model around dedicated program management and intelligent workflows. A single leadership team owns planning, execution, communication, risk management and delivery at every stage, from licensing through to global deployment. "Bringing eCOA translation, linguistic validation and rater training together under one program team is exactly the kind of service model global clinical trials need," said Martial Marcotti, EVP & Chief Product Officer at Kayentis, a leading eCOA vendor. "Across many studies and therapeutic areas, we've come to rely on RWS as a trusted partner because they understand both the operational pressure sponsors face and the quality standards regulated research demands. An integrated approach like this can simplify global study execution, reduce handoffs and help sponsors move faster without compromising endpoint quality, compliance or the patient experience." As part of this transformation, RWS has expanded its digital health portfolio to include rater training, bringing together COA licensing, source validation, linguistic validation, eCOA migration, and rater training into one integrated delivery program. By removing traditional service silos, sponsors benefit from streamlined communication, consistent governance, simplified vendor management, and improved coordination from instrument acquisition through study execution.